BACKGROUND
==========

Autism is a specific form of what is now termed autism spectrum disorder (ASD). ASD is characterized by deficits in communication and social interaction and by stereotypic and rigid behaviors. In addition, macrocephaly, cognitive impairment, and seizures can be associated with ASD. Other brain anatomical abnormalities in autism have been reported in the literature, along with differences in intracranial volumes ([@B10], [@B9]; [@B104]). Pathologically, macrocephaly due to brain enlargement in autism is likely due to cell adhesion dysfunction. The amyloid-β precursor protein (APP), which is better known in association with Alzheimer's disease (AD), is a known cell adhesion and neurite pruning protein ([@B148]; [@B114]). The amyloidogenic pathway favors loss of function APP with sequential cleavage of APP by β-secretase (BACE1) resulting in neurotoxic amyloid-β (Aβ) peptides 40 and 42, the major components of cerebral amyloid plaques associated with brain atrophy found in AD. *Alternative cleavage* via the α secretase non-amyloidogenic pathway releases the non-amyloidogenic secreted APP α (sAPPα; [@B65]), believed to have neurotrophic properties ([@B101]; [@B125]). The expected plasma neuronal marker profile in AD is low sAPPα and high Aβ 40/42. The non-amyloidogenic pathway (represented by high sAPPα and low Aβ 40/42) may represent a gain of function toxicity associated with neurodevelopmental conditions including autism. Of particular interest to autism research, we ([@B138]; [@B125]), and others ([@B14]), have determined that the cleavage product of APP, sAPPα, is elevated in plasma from autistic subjects vs. neurotypical and mildly autistic subjects ([@B125]).

These elevated sAPPα levels and increased intracranial volumes have led to the "anabolic hypothesis" of autism etiology:autism as a product of overgrowth (or insufficient pruning) of cranial neurons, resulting in neurological and behavioral symptoms (**Figure [1](#F1){ref-type="fig"}**). In addition to circumstantial evidence, specific APP pathways support this hypothesis. Fragile X syndrome (FXS), which is commonly marked by a comorbid diagnosis of ASD, involves the disruption of normal interaction between the fragile X mental retardation protein (FMRP) and metabotropic glutamate receptor (mGluR) which misregulates APP mRNA translation ([@B161]). Of note, FXS has been associated with macrocephaly ([@B87]). APP and metabolites also have a purported anabolic role within other translation regulating pathways such as Ras small GTPase/extracellular signal-regulated kinase (Ras/ERK; [@B154]; [@B127]) and phosphoinositide 3 kinase/mammalian target of rapamycin (P13K/mTOR; [@B127]; [@B21]).

![**Contrast of normal and pathogenic APP protein processing pathways.** **(A)** Normal pathway. APP protein (green) is processed by secretases (violet) and usually cleaved at the α-secretase site by ADAM10 or ADAM17 (α), then afterwards by the γ-secretase complex (γ). This produces sAPPα, the non-pathogenic p3 peptide product, and the APP intracellular domain (AICD). The sAPPα product is both neuroprotective and activates microglia. These balanced processes, under normal conditions, lead to neural pruning and normal development at appropriate times. This is the majority APP processing pathway. **(B)** APP anabolic dysfunction of the α-secretase pathway, specifically anabolic proteins/peptide levels, processes, and outcomes indicated in yellow. Overproduction of APP and/or excess α-secretase activity results in overproduction of sAPPα, which both activates neuroglia and is neuroprotective. Neuroprotective activity would presumably overwhelm microglial activation, since other molecules, presumably not also over-produced in this scenario, also activate microglia during neural pruning and would not be able to make up the difference to overwhelm additional sAPPα neuroprotection. The net result would bring about neuronal overgrowth and risk for autism. **(C)** The "catabolic"/neurodegenerative amyloidogenic β-secretase pathway, specifically catabolic protein/peptide levels, processes, and outcomes indicated in red. This pathway is associated with neurodegeneration and Alzheimer's disease. Possible increase in APP protein and BACE1 protein levels (β) result in greater cleavage at the β-secretase and then by γ-secretase complex (γ). This produces sAPPβ, pathogenic/neurotoxic Aβ peptide, and AICD. sAPPβ activates microglia without offering neuroprotection. Thus, two of the three major products of the β-secretase pathway are neurodegenerative. If the β-secretase pathway becomes excessive, risk for Alzheimer's disease increases.](fncel-07-00094-g001){#F1}

The anabolic hypothesis of autism etiology provides specific molecular mechanisms for the development of ASD. Since the hypothesis is based upon levels of gene expression/translation, it has greater explanatory power than genetic mutation models. Likewise, recent years have seen greater recognition of environmental influences on gene expression, such as the enviromic/epigenomic latent early-life associated regulation (LEARn) model ([@B84]). Genetic predisposition would be conditioned by environmental risk to produce overall risk for autism and likewise point to potential preventative and treatment methods based on solid biochemical and neurological understanding of this disorder.

AUTISM AS AN EARLY NEURODEVELOPMENTAL DISORDER
==============================================

Autism is characterized by deficits in communication and social interaction and by stereotypic and rigid repetitive behaviors. Prevalence of ASD in the United States is estimated to be between 1 in 50 ([@B23]) and 1 in 88 ([@B7]). Diagnosis can be made reliably as early as ages 18--24 months, with symptoms of autism seen as early as 9--12 months ([@B73]). Infants with autism often show delayed onset of babbling, decreased gestures, imitation, and responsiveness within the first year. In the second and third years, there often is decreased frequency and diversity of language, less "showing" and "pretend" behaviors and reduced "joint attention," considered a unique, core feature of autism ([@B86]). One in four children with autism may demonstrate word loss and other signs of communication regression during toddlerhood ([@B93]). Word loss stands out as a "red flag" and is considered unique to autism ([@B93]). This early presentation of symptoms suggests an associated prenatal/early childhood disruption of brain function that may underlie symptoms.

APP IN EARLY BRAIN DEVELOPMENT
==============================

APP is a large (695--770 amino acid) glycoprotein produced in brain microglia, astrocytes, oligodendrocytes, and neurons ([@B108]). It has a large extracytoplasmic domain, a membrane-spanning domain containing the Aβ-peptide, and a short intracytoplasmic domain ([@B74]). Mature APP is axonally transported and can be secreted from axon terminals in response to synaptic activation ([@B101]) where it may play a role in neuronal maturation and synaptogenesis ([@B123]).

Proliferation, migration, differentiation, myelination, and synaptogenesis are all steps involved in generation of a mature neuron. Some of the known functions of APP in these processes include promotion of proliferation, cell--cell adhesion ([@B131]), migration ([@B101]), and synaptogenesis ([@B123]). More to the point, sAPPα has specific activity in inducing cellular proliferation ([@B137]), including neural progenitor cells ([@B45]). sAPPα facilitates substrate adhesion in cell culture ([@B160]). Induction of neuroprogenitor migration by sAPPα may be due to sAPPα upregulation of C--C chemokine levels ([@B157]). sAPPα induces synaptogenesis in response to increases in ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10; α-secretase) levels ([@B20]).

APP is predominantly located at synapses ([@B123]) and is released from neurons in an activity-driven fashion ([@B103]). mGluR type 1 and type 5 (mGluR1/5) activation increases secretion of APP in cell culture ([@B74]). The expression of APP appears to be developmentally controlled, with highest levels occurring early in synaptogenesis ([@B123]). APP levels are higher post-natally rather than prenatally but peak before 1 month of age in rodents ([@B85]). APP plays a functional role during growth cone development and has been implicated in neurite outgrowth ([@B108]; [@B103]). APP works in opposition to NMDA (*N*-methyl-[D]{.smallcaps}-aspartate) and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors with respect to glutamate's pruning effects on growth cones ([@B103]). Notably, APP blocks and reverses the ability of glutamate to inhibit dendrite outgrowth in embryonic rat hippocampal cell cultures ([@B101]).

Knockdown of APP inhibits neuronal migration from the cortical ventricular zone to the cortical plate in mice ([@B164]). Conversely, overexpression of APP accelerates migration of neuronal precursor cells into the cortex ([@B164]). In cell culture, APP has been linked to suppression of neuronal cell adhesion ([@B131]). Therefore, the location of APP at the synapse and its developmental function in migration and suppression of cell adhesion support the hypothesis that dysregulated levels of APP contribute to unguided brain growth as seen in autism ([@B40]). APP's location at synaptic dendrites, its regulation by translation repressors such as FMRP, its participation in post-translational modification, and its role in neurogenesis and migration make it a prime candidate to contribute to the synaptic disruption in autism.

PROCESSING OF APP
=================

Amyloid-β precursor protein is best known in association with AD. Sequential cleavage of APP by the β-secretase, β-site APP cleaving enzyme 1 (BACE1) and the γ-secretase complex (presenilin 1, presenilin 2, nicastrin, anterior pharynx defective 1 homolog A, and other uncharacterized subunits) releases sAPPβ, the APP intracellular domain (AICD) and amyloidogenic Aβ peptide (**Figure [1C](#F1){ref-type="fig"}**), the major component of extracellular plaques found in AD ([@B148]).

Although APP-related research is generally in the context of AD pathogenesis, the non-amyloidogenic (non-Aβ) "alpha" route is actually the predominant pathway for APP processing ([@B121]). Its rate-limiting enzyme is the α-secretase family of "a disintegrin and metalloprotease" (ADAM) proteins (ADAM9, 10, and 17; [@B47]; [@B155]). In addition to potential "anti-pruning" activity, ADAM17 induces cellular proliferation in a variety of conditions ([@B61]; [@B91]). Release of sAPPα is complete by the γ-secretase complex ([@B82]; [@B148]), along with the non-amyloidogenic 3 kDa "p3" peptide and the AICD (**Figure [1A](#F1){ref-type="fig"}**). sAPPα exhibits a wide array of neurotrophic activities ([@B102]; [@B150]), important for neurodevelopment. sAPPα activates microglia, a function it shares with sAPPβ ([@B17]). In mice, sAPPα increases neurite outgrowth and memory and protects against multiple insults ([@B145]). It has been suspected that APP contributes to the predisposition to hematologic malignancy in Down syndrome patients and that APP aberration might predispose to cancer ([@B107]). APP is among the most overexpressed genes in acute myeloid leukemia patients with complex karyotypes ([@B15]) and in solid tumors ([@B6]; [@B81]). Promotion of the non-amyloidogenic pathway may be a promising novel treatment in AD ([@B16]). Recently, there has been interest in the function of sAPPα in neurodevelopment and its relationship to autism ([@B138]) and FXS ([@B161]). No specific tie has been found between p3 or AICD and autism.

ADAM17 is also involved in the processing of tumor necrosis TNF-α (tumor necrosis factor-alpha) at both the cell surface and within the trans-Golgi network ([@B22]). This process, known as "shedding," involves cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-α), and is of known physiological importance ([@B22]), particularly in neoplastic proliferation ([@B163]; [@B165]). While ADAM17 itself has not been specifically studied in association with autism, the cerebrospinal fluid to serum ratio for TNF-α is elevated in subjects with autism compared to other pathological states ([@B38]). Furthermore, linkage was found between a region of human chromosome 2 that contains the ADAM17 gene and autism ([@B4]).

GENETICS OF AUTISM
==================

Twin studies, family studies, and predominately male distribution of the disorder attest to the heritability of autism. Twin studies have consistently shown that monozygotic twins are up to 10 times more likely to be concordant for autism than are dizygotic ([@B58]; [@B144]; [@B12]). This rate can be evaluated in comparison to other neurobiological disorders such as AD, depression, bipolar disorder, and schizophrenia (between 2:1 and 4:1), indicating a high heritability for autism ([@B60]; [@B116]). However, the significantly earlier-life pathogenesis of autism vs. these other disorders means that one cannot automatically exclude environmental "protective" influences potentially reducing net genetic influence on heritability in AD, schizophrenia, etc. Family studies ([@B119]; [@B128]) suggest that the risk of autism is 20--60% higher in siblings compared to in the general population. In addition, first degree relatives of individuals with autism were shown to be shy, aloof, and have problematic pragmatic language ([@B128]), consistent with segregation of sub-threshold traits within these families ([@B1]). These and other associations have led to the definition of a "broad autism phenotype," which would suggest classifying autism as extreme manifestation of a normal human variation ([@B146]) rather than inherently pathological in all its traits.

Autism affects more boys than girls (4:1), a finding that has remained consistent since Kanner's first description in 1945, despite the increasing prevalence of its diagnosis. The predominantly male ratio has been attributed to abnormality on the X chromosome, or to sex linkage or genomic imprinting ([@B96]). However, such linkage has not been found in all cases of autism, suggesting the importance of genetic pathways other than the X chromosome. With rare exceptions, however, autism does not appear to be the action of a single gene inherited in a strictly Mendelian pattern, be it autosomal dominant, autosomal recessive, or X-linked ([@B115]).

So-called "rare" genetic variants may contribute to autism ([@B156]), although "rare" variants (disregarding specific disease associations) are overall quite common, with an estimated frequency of up to 3.4 such variants per person ([@B111]). Cytogenetic, gene association, linkage, microarray technology, copy number variation (CNV) analysis and exome sequencing lead to estimates of chromosomal abnormalities in autism that range from 6 to40% ([@B97]; [@B116]; [@B2]). Chromosome regions associated with autism include chr2q37, chr7q22, chr10q23, chr17q11-21, chr22q11, chr22q13, and chr15q11-13 ([@B140]). Non-additive interaction among genes (epistasis) has been proposed to account for such a large range of chromosomal abnormality estimation ([@B120]; [@B129]). Of course, this leads to the inescapable question, what accounts for the remaining 94--60% of autism not associated with chromosomal abnormalities? While numerous studies identifying candidate genes or markers have been reported, very few have been replicated ([@B94]). One solution to this problem is to study endophenotypes associated with autism ([@B53]; [@B44]). None of the endophenotype studies has produced a "definitive" solution. Instead of continuing down a single-cause (DNA mutation) path, it may be more useful to presume that autism is a complex disorder that depends upon interaction of multiple levels of organization, not amenable to simple genetic modeling.

BRAIN ABNORMALITY IN AUTISM: HISTOLOGY AND *POST-MORTEM* ANATOMY
================================================================

Little to no abnormality is revealed by standard hematoxylin and eosin staining of autistic brain tissue ([@B30]). Complex assessment is necessary to reliably determine differences, and research has required many samples to separate autistic from controls. *Post-mortem* brain studies of autism have been hindered by small sample sizes, with fewer than 150 autism cases studied to date, the majority of them adults. Therefore, the peak aberrant neurological growth identified by magnetic resonance imaging (MRI) studies has not yet been confirmed via neuropathology ([@B135]). Often, findings cannot be repeated because the numbers of deaths is low in this group, and death is often due to a cause that is likely to have an effect on the histopathology, e. g., seizures.

These difficulties notwithstanding, in *post-mortem* studies, evidence of autism-associated brain pathology includes disordered interregional connectivity ([@B42]), including reduction in the size of the corpus callosum ([@B54]), minicolumn pathology ([@B33]), deranged neuronal development ([@B18]; [@B153]), and brain cytoarchitecture ([@B18]), and irregularity in brain structures associated with social behavior ([@B143]; [@B159]). Macrocephaly is one of the most widely replicated biological findings in autism, affecting up to 20% of children with the condition ([@B10], [@B9]; [@B104]) and confirmed by MRI volumetric studies, described below ([@B118]; [@B41]; [@B9]; [@B139]) and increased brain weight ([@B18]; [@B13]). While occipital-frontal head circumference (OFC) appears normal at birth, excessive brain growth occurs early, around the time symptoms appear. Later growth may plateau or decline to normal circumference in adulthood ([@B104]). Proposed mechanisms underlying brain enlargement include overproduction of synapses, failure of synaptic pruning, excessive neurogenesis and gliogenesis, or reduction in cell death ([@B104])

Pathological studies of the frontal lobes of autistic brains, which subserve social relatedness, the ability to change set, and the persistence of repetitive behaviors, show increased microglial activation ([@B152]), and volume ([@B106]), indicating potential neuroinflammation. Frontal lobe spindle neurons ([@B135]), showed no differences in adults ([@B79]), but there was an increased ratio of spindle neurons to pyramidal neurons in children ([@B130]). In adults, a poorly defined boundary was found at the frontal, parietal, and temporal lobe gray-white matter junctions, suggestive of abnormalities in neurogenesis or neuronal migration ([@B8]).

Minicolumns, also known as microcolumns, are vertical columns of neurons organized into pathways and intrinsic circuits with a similar receptive field ([@B28], [@B27]). [@B31]found significant differences between the brains of autistic patients and controls in the number of minicolumns, in the horizontal spacing that separates cell columns, and in their internal structure. These findings have been essentially replicated ([@B27]; [@B33]) and indicate that excess proliferation of neurons early in development is followed by a decrease in dendritic arborization, accounting for early overgrowth followed by normal brain volume in autism ([@B135]). However, [@B32]) later comparison of the minicolumns of three internationally distinguished neuroscientists vs. six non-scientist controls showed a minicolumn pattern similar to what they found for autism, although none of the scientists had reported autism-like symptomology. This was explained by noting that narrower minicolumns may favor discrimination and focused attention, two traits necessary for scientific achievement. On the other hand, autistic brains also have poorly synchronized and weak connectivity between brain regions. For example weak connectivity has been reported between the frontal cortex that supports decision making, the left temporal lobe that supports speech, and right temporal lobe that supports visual-spatial recognition ([@B42]). This may explain how individuals with autism may lack facial recognition and have trouble verbally expressing their ideas. Human APP and *Drosophila* equivalent APPL can induce post-developmental axonal arborization in the *Drosophila* CNS after brain damage ([@B89]). Further, APP has been associated with neurogenesis and neuronal migration ([@B103]). Of particular note, knockdown of APP alters recruitment of interneurons in L5 and affects their laminar distribution ([@B92]), which would likewise alter organization and integration of neurons into functional neural circuits. While sAPPα has not yet been studied in regard to microcolumnar organization, amyloid-β deposits have been shown to contribute to loss of microcolumnar organization ([@B24]). APP may play a role in neuronal network connectivity; it's specific role in minicolumn development remains to be determined.

There has been much work on neuropathology in the amygdala, known to be involved with the perception of fear, anxiety, and obsession-compulsion that would interfere with social relations. [@B78]found unusually small, densely packed neurons in amygdale from older children and adults with autism compared to controls. [@B132]found fewer neurons in the total amygdala but no increase in neuronal density or decrease in the size of neurons from old children and adults. It has been speculated that an excessive number of neurons would be initially generated during early development with their subsequent elimination during adulthood ([@B135]). This could explain inconsistent findings between the neuropathology studies and the amygdala enlargement reported in the brain MRIs of younger children with autism ([@B142]; [@B134]; [@B132]).

BRAIN ABNORMALITY IN AUTISM: FINDINGS FROM MAGNETIC RESONANCE IMAGING
=====================================================================

Brain MRI studies indicate that very young children with autism (ages 18 months to 4 years) have a 5--10% abnormal enlargement in total brain volume ([@B41], [@B40]; [@B142]), although increased size of the adult brain also has been reported ([@B118]). In addition, cross-sectional and longitudinal specific enlargement of the frontal and temporal lobes has been found in 2 year olds with autism ([@B133]), and increased size of the adult brain also has been reported ([@B118]). The amygdala also undergoes developmental enlargement in young boys with autism ([@B142]; [@B134]) and later follows a growth trajectory different from controls. A recent longitudinal study of 38 children with autism and 21 controls showed enlargement of cortical volume (surface area), but not cortical thickness at age two compared to ages 4 and 5 ([@B67]). Cortical surface area was linked to the number of minicolumns in the cortical layer ([@B124]), while cortical thickness is thought to reflect dendritic arborization ([@B70]).

MECHANISMS OF APP IN AUTISM
===========================

We have previously reported high levels of total plasma sAPP (including sAPPα) in a small sample of young children with severe autism and aggression ([@B138]). These children expressed sAPP at two or more times the levels of children without autism and up to four times more than children with mild autism. Overall, there was a trend towards higher levels of both sAPPα and total sAPP in children with autism, combined with a non-significant decrease in Aβ40. This pointed toward the possibility of increased non-amyloidogenic (growth-promoting or anabolic) processing in autism. These findings have been replicated and extended by an independent laboratory: Elevated plasma sAPPα was found in 60% of known autism children (*n* = 25) compared to healthy age-matched controls ([@B14]). A recent follow up by our laboratory in a separate, larger set of autism and control patient plasma samples (16 autism, 18 control), confirmed the original finding of significantly elevated sAPPα in plasma of severe autism patients, although without coexistant aggression ([@B125]). Elevation in sAPPα was not found with mild autism in either study. Crucially, this work showed a decrease in levels of both Aβ40 and Aβ42 in severely autistic patients compared to controls.

In summary, APP is regulated by FMRP via the mGluR receptor ([@B161]). Functional consequences of excessive mGluR signaling in absence of FMRP include prolongation of epileptic form bursts in hippocampal area CA3 ([@B14]), elongation of dendritic spines on cultured hippocampal neurons ([@B151]) and long-term depression (LTD) in hippocampal area CA1 ([@B90]). These findings are associated with the FXS clinical phenotypes: epilepsy, elongated and immature dendritic spines, and cognitive delay, according to the mGluR theory of FXS ([@B19]).

If mGluR5 signaling is enhanced in FXS individuals, excessive APP translation would be expected, inevitably leading to higher sAPPα levels. As evidence shows that excessive mGluR5 signals favors an excitatory, anabolic state in FXS, we speculate that overexpression of the mGlur5 pathway and resultant higher sAPPα levels may likewise contribute to aggression, seizures, and intellectual deficit seen in severe autism. Further, it is hypothesized that such anabolism may contribute to brain overgrowth associated with autism.

One mechanism by which sAPPα could contribute to brain overgrowth is by disrupting cell adhesion. [@B67]showed that early brain enlargement typical of autism may be associated with increased surface area overgrowth due to faulty cell adhesion. One such mechanism would be faulty adhesion molecule β-catenin, a component of the cadherin protein complex that constitutes adherens junctions. Adhesion molecules are thought to reduce growth of brain progenitor cells. APP modulates β-catenin degradation *in vitro* and *in vivo* ([@B36]). Evidence also suggests that molecular defects in autism interfere with synaptic protein synthesis ([@B77]). Defects in translational repression would favor an anabolic state, underlying the autistic phenotypes of macrocephaly, cognitive impairment, and seizures.

APP AND FMRP
============

Protein synthesis is reduced in FXS, a rare neurodevelopmental condition (1 in 4000 males and 1 in 10,000 females; National Fragile X Foundation, 2013), associated with intellectual disability, and ASD in 2 in 3 males with FXS ([@B66]). FXS is caused by a trinucleotide repeat (CGG repetitive sequence) in the promoter region of the fragile X mental retardation 1 gene (FMR1). This gene's product, FMRP, is important for normal brain development. FMRP is an RNA binding and carrier protein that carries the messages produced from many other genes to the synapse. FMRP is involved in both activity-dependent transport of target mRNAs and in regulation of local protein synthesis at the synapse ([@B11]). Local protein synthesis following synaptic activity is necessary for maintenance of some plastic changes at the synapse and likely it is important for changes in spine morphology ([@B63]). Therefore, FMRP-mediated regulation of local protein synthesis is presumably essential for normal memory and learning.

Fragile X mental retardation protein can be synthesized locally in proximal dendrites ([@B56]), or recruited to the synapse from more distant sites after mGluR activation ([@B43]). mGluR1/5 receptors are positioned in the post-synaptic membrane, where they activate a Gq-coupled second messenger system that transduces glutamate release into downstream phosphorylation cascades. Activation can lead to either long-term potentiation (LTP) or LTD depending on cell type and brain location. Activation of mGluR5 releases FMRP-mediated translation repression and results in protein synthesis-dependent LTD ([@B19]). Functional consequences of excessive mGluR signaling in absence of FMRP include prolongation of epileptic form bursts in hippocampal area CA3 ([@B14]), elongation of dendritic spines on cultured hippocampal neurons ([@B151]), and LTD in hippocampal area CA1 ([@B90]). These findings are associated with the FXS clinical phenotypes: epilepsy, elongated, and immature dendritic spines, and cognitive delay, according to the mGluR theory of FXS ([@B19]).

In the resting state, FMRP binds to and inhibits dendritic translation of up to 4% of brain mRNAs including APP ([@B46]). APP is regulated by FMRP via the mGluR receptor ([@B161]). If mGluR5 signaling is enhanced in autistic individuals, excessive APP translation would be expected, inevitably leading to higher sAPPα levels. Recently, we found elevated sAPPα in the plasma of children with FXS (*n* = 18) compared to typically developing, age-matched controls (*n* = 18; [@B83]). Further, levels of Aβ40 and Aβ42 were higher in FXS compared to controls ([@B83]). Preliminary evidence for this same pattern, i.e., high levels of sAPPα and Aβ, was found for a very small sample of left temporal lobe brain tissue of FXS (*n* = 2) compared to typically developing, age-matched control (*n* = 1). These results suggest investigating whether FXS receives a "double dose" of deleterious components from non-amyloidogenic and amyloidogenic pathways. Aβ40 and Aβ42 levels were significantly higher in two strains of fmr-1 knockout mice compared to wild type ([@B161]). Genetic downregulation of mGluR5 signaling has reversed behavioral deficits in fmr-1 knockout mice ([@B51]; [@B50]). Simple mGluR5 antagonism, predicted to reduce APP via the anabolic pathway ([@B141]), may reverse these effects in humans.

APP IN THE Ras/ERK AND PI3K/Atk/mTOR PATHWAYS
=============================================

The Ras small GTPase/extracellular signal-regulated kinase (Ras/ERK) and phosphoinositide 3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathways pair synaptic activity to the translational machinery and are also involved in protein synthesis-dependent LTP and LTD ([@B77]). Mutation of the proteins which regulate these pathways associates with high prevalence of autism and intellectual deficit ([@B88]). Inactivating mutations of several negative regulators of the ERK and mTOR pathways, such as neurofibromin (neurofibromatosis type 1), harmartin, and tuberin (tuberous sclerosis), and PTEN (phosphatase and tensin homolog) are responsible for genetic disorders with a high prevalence of cognitive impairment and autism ([@B88]). In the absence of functional proteins, these pathways are "turned on" to excess. These signaling pathways are activated not only by mGluR receptors, but also NMDA and neurotrophin Trk receptors ([@B77]). Ras/ERK is activated by sAPPα ([@B45]), its secretase ADAM17 ([@B49]), and neurotrophin Trk receptors. TrkB has the highest affinity to the binding of brain-derived neurotrophic factor (BDNF), a growth factor with important roles in the survival and function of neurons and linked to both ASD and AD ([@B113]). Indeed, effects of acamprosate (*N*-acetyl-homotaurine) on behavior and BDNF recently has been studied in youth with FXS (Erickson et al., 2013). The researchers suggested that the increased BDNF levels with treatment may serve as a useful pharmacodynamic marker, which is consistent with the proposed anabolic model. It would be interesting to test whether a change in sAPPα levels could serve as another important pharmacodynamic marker in neurodevelopmental disorders.

The PI3K/Akt/mTOR pathway is an FMRP-dependent pathway ([@B109]). PTEN is a negative regulator of the PI3K pathway. PTEN mutation phenotypes include brain tumors, macrocephaly, and autism ([@B25]; [@B80]). There is evidence that sAPPα, specifically, induces cellular proliferation through the PI3K/mTOR pathway ([@B37]), and sAPPα activates Akt ([@B45]).

APP AND PROTEIN KINASE C
========================

Reduced activity of protein kinase C (PKC) associates with regressive autism ([@B71]). A linear relationship has been noted between reduction in PKC activity and restricted, repetitive, and stereotyped behaviors ([@B71]). Likewise, specific haplotypes in the protein kinase c-β (PRKB1) gene are associated with autism ([@B117]). Protein phosphorylation by kinases including PKC drives APP processing toward the anabolic α-secretase pathway ([@B26]; [@B29]). This apparently contradicts the anabolic hypothesis and would require further study.

THE UNIFYING EPIGENETIC LEARn MODEL IN AUTISM
=============================================

Amyloid-β precursor protein's role in FMRP, ERK, and mTOR pathways is consistent with an overall, pro-growth, anti-apoptotic role for APP. In a situation of nerve growth factor withdrawal, Aβ production is upregulated, leading to neuronal apoptosis ([@B100]). In this way, APP activates both trophic (through sAPPα) and apoptotic (through Aβ) pathways, and the predominance of one may determine pathology: autism vs. AD. The finding that the same gene can promote anabolism and catabolism is reminiscent of FMRP's role in FXS and Fragile X-associated tremor/ataxia syndrome (FXTAS) found in subsets of older adults harboring FMR1 premutations ([@B64]). FXTAS is a condition of progressive tremor and ataxia in individuals who show no pre-morbid cognitive deficits, developing over the age of 50. Dementia occurs in a subset of those with FXTAS. It is believed that FXS is caused by FMRP loss of function, and FXTAS is caused by an FMR1 mRNA gain of function toxicity ([@B141]). In the case of APP, loss of function would favor the amyloidogenic pathway leading to AD while gain of function toxicity would favor the non-amyloidogenic pathway leading to excessive ADAM17, sAPPα, and brain overgrowth associated with autism.

Autism is a complicated disorder for which many models combining genetic and external factors have been proposed ([@B112]; [@B1]; [@B116]). A key point of the anabolic hypothesis is that, unlike many genetic models, it is not a "change of function" model. Genetic models based on coding sequence variation have generally presupposed that a pathogenic variant results in loss or gain of function for a protein. The anabolic hypothesis, on the other hand, does not propose qualitative differences in the activities of the participating molecules. Instead, it is a quantitative model. Variation in activity *levels* spells the difference between health and disorder. Qualitative mutation in associated proteins could be informative, particularly loss of function mutations, as these would effectively mimic variations that result in atypically low levels of a protein of interest. Likewise, gain of function mutations could essentially mimic effects of atypically high levels of a protein, which permit a minority function to reach a critical threshold.

Our basis for preferring an epigenetic explanation is a response to dead ends and results from purely genetic models that fell very far short of original expectations. Laying out matters plainly, no genetic model has proved adequate to explain non-syndromic autism, the condition's most common form. Ever-finer, ever-broader GWAS or other genetic studies have repeatedly failed to find the magic target. As a result, models have had to resort to ever-more Byzantine multi-gene invocations ([@B3]; [@B5]). We propose an epigenetic model specifically in the face of the failure of purely genetic presumptions, which may have come to the point of invoking a "hidden variable" argument analogous to those used by opponents of quantum physics.

Many of the proteins implicated in the anabolic hypothesis are subject to or take part in epigenetic regulation. *FMR1* has multiple phenotypes depending upon variable DNA methylation ([@B48]). Regulation of critical APP protein processing enzymes was altered by changes in DNA methylation ([@B59]). ERK/mitogen-activated protein kinases (MAPK) signaling activity drives epigenetic modification that underlies stress, learning, and memory processes ([@B149]). It is now accepted that epigenetic states can change after birth, including by age-related drift ([@B98]) and specific changes associated with late-life neurological disorders, such as AD ([@B122]; [@B158]). Epigenetic changes can occur in response to environmental stressors, such as exposure to heavy metals ([@B162]) and famine ([@B69]; [@B99]). Of particular interest is that these exposures can have occurred in the previous generation, before conception, with effects passed along to offspring ([@B57]).

In addition to the already-mentioned effect of DNA methylation status on *FMR1*-associated phenotypes ([@B48]), abnormal DNA methylation was found in the 5′-CpG island for the UBE3A gene of autistic subjects ([@B72]). The oxytocin receptor gene has aberrant DNA methylation in its CpG island, depending upon autism status ([@B62]). These specific differences were reflected in a wider scale across prefrontal cortex neurons, which showed changes in chromatin structure at multiple gene loci associated with neuronal connectivity, social behaviors, and cognition, with altered levels of corresponding transcripts ([@B136]). Even the X chromosome association explanation for the predominance of male autistic patients has been questioned on epigenetic grounds. Specifically, sex hormone activity mediates epigenetic modifications of DNA and histones, increasing or decreasing risk of various diseases, such as autism ([@B76]).

Finally, to address the function of APP-in the anabolic hypothesis, while evidence exists for levels of anabolic forms of APP (e.g., sAPPα) to contribute to autism, as we have outlined herein, no specific genetic link has as of yet been reported in the literature. We suggest that lack of discovery may be due to lack of presence. A testable alternative hypothesis to explain APP's role would be epigenetic pathways.

Many workers have proposed that autism is a result of complex interaction between genetic and environmental factors ([@B112]; [@B39]; [@B52]). A specific, testable expression of such concepts would be the LEARn model ([@B84]; [@B95]) in which complex neurological disorders require multiple "hits" to clinically manifest. Earlier hits would be latent epigenetic markers until sufficient critical hits are accumulated by a necessary life span cutoff point, at which time a disorder would become apparent. Should insufficient hits be suffered, or should hits be successfully detected and remediated before the developmental threshold occurs, no disease would appear.

In terms of autism, hits of interest could be those of early post-natal development, particularly any that turned out to be associated with DNA oxidation or DNA hypomethylation. These two particular environmentally induced gene sequence lesions have already been shown to be amenable to dietary remediation by addition of *S*-adenosyl methionine, which resulted in reversal of induced hypomethylation ([@B126]; [@B35]; [@B68]; [@B75]). Likewise DNA methylation status can be altered by social interaction, such as differences in maternal care and rearing practices ([@B147]; [@B34]; [@B105]). LEARn-informed research could produce rational relationships for therapy and brain biochemistry in autism and early autistic conditions.

CONCLUSION
==========

It is impossible to reduce ASDs to a direct, short-term etiology or collection of simple factors. Instead, etiology of multiple pathways and gene products probably underlie the condition. This is not to say that none of these could be critical. One such possible fundamental target would be APP at the nexus of neuroproliferation and neural pruning and its interaction with networks such as FMRP/mGluR, ERK/MAPK, and PI3K/mTOR (**Figure [2](#F2){ref-type="fig"}**). This presents a possible handle upon autism etiology, should sAPPα contribute to anabolic pathogenesis of the disorder. Of particular value is the evidence that APP dysfunction is more likely due to environmental/epigenetic interaction rather than strict genetic variation. Such dependency may permit environmental, e.g., dietary, remediation, as mentioned herein, and possible reversal at early stages of a disorder.

![**sAPPα as a network activator in anabolic etiology of autism**. The sAPPα product has multiple functions that can contribute to neuronal overgrowth and increase risk of autism. Specifically, sAPPα, produced by α-secretase activity of proteins such as ADAM17, acts on its own as a cell growth factor, stimulates neuronal migration, induces synaptogenesis, and promotes cellular adhesion, all of which lead to neuroproliferation. In addition, sAPPα activates ERK and Akt, which in turn also lead to neuroproliferation. **(A)** Under normal development, these processes result in normal growth. **(B)** sAPPα can contribute to anabolic etiology of autism through several potential pathways, including overexpression of APP. Such overexpression could be from derepression via FMRP deficiency, as in FXS. It must be stressed that this is not the only possible cause of APP overexpression and is cited simply as one of many potential examples. Increase in APP would lead to greater sAPPα through the already dominant α-secretase pathway. This would directly and indirectly lead to excess neuroproliferation through multiple pathways, which would contribute to autism.](fncel-07-00094-g002){#F2}
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AD

:   Alzheimer's disease

ADAM

:   a disintegrin and metalloproteinase

AICD

:   APP intracellular domain

APP

:   amyloid-β precursor protein

ASD

:   autism spectrum of neurodevelopmental disorders

Aβ

:   amyloid-β peptide

FMR1

:   fragile X mental retardation 1 gene

FMRP

:   fragile X mental retardation protein

FXS

:   Fragile X syndrome

FXTAS

:   fragile X-associated tremor/ataxia syndrome

LEARn

:   latent early-life associated regulation

mGluR

:   metabotropic glutamate receptor; MRI, magnetic resonance imaging.

PI3K/mTOR

:   phosphoinositide 3 kinase/mammalian target of rapamycin

PKC

:   protein kinase C

PRKB1

:   protein kinase c-β gene

Ras/ERK

:   Ras small GTPase/extracellular signal-regulated kinase

sAPPα

:   soluble APP α

TACE

:   tumor necrosis factor-α converting enzyme

TIV

:   total intracranial volume

TNF-α

:   tumor necrosis factor α.
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